Treatment of metastatic colorectal cancer with or without bevacizumab: can theneutrophil/lymphocyte ratio predict the efficiency of bevacizumab?

dc.contributor.authors	Dirican A, Varol U, Kucukzeybek Y, Alacacioglu A, Erten C, Somali I, Can A,Demir L, Bayoglu IV, Akyol M, Yildiz Y, Koyuncu B, Coban E, Tarhan MO
dc.date.accessioned	2020-02-27T08:41:16Z
dc.date.available	2020-02-27T08:41:16Z
dc.date.issued	2014
dc.identifier.citation	Dirican A, Varol U, Kucukzeybek Y, Alacacioglu A, Erten C, Somali I, Can A,Demir L, Bayoglu IV, Akyol M, Yildiz Y, Koyuncu B, Coban E, Tarhan MO (2014). Treatment of metastatic colorectal cancer with or without bevacizumab: can theneutrophil/lymphocyte ratio predict the efficiency of bevacizumab?. Asian Pac JCancer Prev, 15(12), 6-4781
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66719
dc.title	Treatment of metastatic colorectal cancer with or without bevacizumab: can theneutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
dc.identifier.volume	15(12)
dc.identifier.startpage	4781
dc.identifier.endpage	6
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Bayoğlu, İbrahim Vedat
dc.relation.journal	Asian Pac JCancer Prev
dc.contributor.author	Bayoğlu, İbrahim Vedat